250 related articles for article (PubMed ID: 8035933)
1. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
[TBL] [Abstract][Full Text] [Related]
2. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.
Ruottinen HM; Rinne JO; Ruotsalainen UH; Bergman JR; Oikonen VJ; Haaparanta MT; Solin OH; Laihinen AO; Rinne UK
J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):91-106. PubMed ID: 9620057
[TBL] [Abstract][Full Text] [Related]
3. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
Pauwels T; Dethy S; Goldman S; Monclus M; Luxen A
Eur J Pharmacol; 1994 May; 257(1-2):53-8. PubMed ID: 8082707
[TBL] [Abstract][Full Text] [Related]
4. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
[TBL] [Abstract][Full Text] [Related]
5. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
[TBL] [Abstract][Full Text] [Related]
6. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
[TBL] [Abstract][Full Text] [Related]
7. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
[TBL] [Abstract][Full Text] [Related]
8. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
Laihinen A; Rinne JO; Rinne UK; Haaparanta M; Ruotsalainen U; Bergman J; Solin O
Neurology; 1992 Jan; 42(1):199-203. PubMed ID: 1734304
[TBL] [Abstract][Full Text] [Related]
9. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.
Léger G; Gjedde A; Kuwabara H; Guttman M; Cumming P
Synapse; 1998 Dec; 30(4):351-61. PubMed ID: 9826227
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
11. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
12. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
[TBL] [Abstract][Full Text] [Related]
13. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
Smith LA; Gordin A; Jenner P; Marsden CD
Mov Disord; 1997 Nov; 12(6):935-45. PubMed ID: 9399218
[TBL] [Abstract][Full Text] [Related]
14. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
[TBL] [Abstract][Full Text] [Related]
15. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
16. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
18. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
[TBL] [Abstract][Full Text] [Related]
20. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.
Cumming P; Boyes BE; Martin WR; Adam M; Ruth TJ; McGeer EG
Biochem Pharmacol; 1987 Aug; 36(15):2527-31. PubMed ID: 3111485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
